Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mylotarg salvage monotherapy for children with relapsed or refractory acute myeloid leukemia
NL-OMON21108Phase 2Active, not recruiting
- Sponsor
- Amsterdam UMC, location VUmc
- Start
- Mar 2002
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemtuzumab ozogamicin in acute myeloid leukemia (AML), sponsored by Amsterdam UMC, location VUmc. Primary endpoint: Overall complete response rate. Started Mar 2002; status: active, not recruiting.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON21108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21108.